Citadel Advisors
APLS

Citadel Advisors’s Apellis Pharmaceuticals APLS Stock Holding History

Citadel Advisors’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.27M Buy
155,800
+15,600
+11% +$336K ﹤0.01% 3979
2025
Q4 		$3.52M Sell
140,200
-7,700
-5% -$181K ﹤0.01% 4875
2025
Q3 		$3.35M Buy
147,900
+35,100
+31% +$819K ﹤0.01% 5102
2025
Q2 		$1.95M Buy
112,800
+600
+0.5% +$11.1K ﹤0.01% 5745
2025
Q1 		$2.45M Sell
112,200
-22,100
-16% -$611K ﹤0.01% 5141
2024
Q4 		$4.29M Sell
134,300
-9,600
-7% -$289K ﹤0.01% 4212
2024
Q3 		$4.15M Sell
143,900
-74,400
-34% -$2.76M ﹤0.01% 4258
2024
Q2 		$8.37M Buy
218,300
+80,900
+59% +$3.66M ﹤0.01% 3012
2024
Q1 		$8.08M Sell
137,400
-257,500
-65% -$16.4M ﹤0.01% 3223
2023
Q4 		$23.6M Sell
394,900
-285,000
-42% -$14.5M ﹤0.01% 1849
2023
Q3 		$25.9M Buy
679,900
+549,300
+421% +$24.1M 0.01% 1619
2023
Q2 		$11.9M Sell
130,600
-87,900
-40% -$7.58M ﹤0.01% 2452
2023
Q1 		$14.4M Sell
218,500
-70,700
-24% -$4.08M ﹤0.01% 2320
2022
Q4 		$15M Buy
289,200
+84,900
+42% +$4.5M ﹤0.01% 2293
2022
Q3 		$14M Buy
204,300
+21,900
+12% +$1.3M ﹤0.01% 2310
2022
Q2 		$8.25M Sell
182,400
-23,500
-11% -$1.07M ﹤0.01% 2941
2022
Q1 		$10.5M Sell
205,900
-31,300
-13% -$1.38M ﹤0.01% 2872
2021
Q4 		$11.2M Sell
237,200
-356,700
-60% -$14M ﹤0.01% 2881
2021
Q3 		$19.6M Buy
593,900
+496,100
+507% +$27.9M ﹤0.01% 2026
2021
Q2 		$6.18M Buy
97,800
+33,500
+52% +$1.73M ﹤0.01% 3991
2021
Q1 		$2.76M Buy
64,300
+18,800
+41% +$890K ﹤0.01% 5638
2020
Q4 		$2.6M Buy
45,500
+22,800
+100% +$964K ﹤0.01% 4818
2020
Q3 		$685K Buy
22,700
+7,200
+46% +$215K ﹤0.01% 6730
2020
Q2 		$506K Buy
15,500
+3,600
+30% +$116K ﹤0.01% 7050
2020
Q1 		$319K Sell
11,900
-7,600
-39% -$270K ﹤0.01% 7222
2019
Q4 		$597K Buy
+19,500
New +$540K ﹤0.01% 6530

Other funds holding APLS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Citadel Advisors's APLS Position: Q1 2026 in Review

Citadel Advisors reduced its Apellis Pharmaceuticals (APLS) stake by 94% in Q1 2026, selling an estimated $13.1M and leaving 38,887 shares worth $1.56M. The position accounts for ﹤0.01% of the portfolio, ranked #6621.

Citadel Advisors first reported a position in APLS in Q2 2018 and has held it in 31 quarters since. The position peaked at $82.2M in Q4 2020. 321 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • Citadel Advisors held 38,887 shares of Apellis Pharmaceuticals worth $1.56M as of Q1 2026.
  • Citadel Advisors sold 609,342 Apellis Pharmaceuticals shares in Q1 2026, an estimated $13.1M.
  • Apellis Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #6621 holding.
  • Citadel Advisors first reported a position in Apellis Pharmaceuticals in Q2 2018 and has held it in 31 quarters since.
  • Citadel Advisors's Apellis Pharmaceuticals position peaked at $82.2M in Q4 2020.
  • 321 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.